Results 21 to 30 of about 457,954 (260)

Pancreatic cancer [PDF]

BMJ, 2014
In recent years, it has become clear that the current standard therapeutic options for pancreatic cancer are not adequate and still do not meet the criteria to cure patients suffering from this lethal disease. Although research over the past decade has shown very interesting and promising new therapeutic options for these patients, only minor clinical ...
Ajith K, Siriwardena, Alison M, Siriwardena   +1 more
openaire   +4 more sources

Combined resection of the transpancreatic common hepatic artery preserving the gastric arterial arcade without arterial reconstruction in hepatopancreatoduodenectomy: a case report

Surgical Case Reports, 2018
Background Surgeons sometimes must plan pancreatoduodenectomy (PD) for patients with a variant common hepatic artery (CHA) branching from the superior mesenteric artery (SMA) penetrating the pancreatic parenchyma, known as a transpancreatic CHA (tp-CHA).
Takashi Miyata, Yusuke Yamamoto, Teiichi Sugiura, Yukiyasu Okamura, Takaaki Ito, Ryo Ashida, Sunao Uemura, Yoshiyasu Kato, Katsuhisa Ohgi, Atsushi Kohga, Tsuneyuki Uchida, Shusei Sano, Katsuhiko Uesaka   +12 more
doaj   +1 more source

Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma

Journal of Hematology & Oncology, 2020
Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve as targets in precise therapy.
Yunzhen Qian, Yitao Gong, Zhiyao Fan, Guopei Luo, Qiuyi Huang, Shengming Deng, He Cheng, Kaizhou Jin, Quanxing Ni, Xianjun Yu, Chen Liu   +10 more
doaj   +1 more source

Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma

Cancer Cell International, 2021
Background High tumor mutation burden (TMB) has gradually become a sensitive biomarker for predicting the response to immunotherapy in many cancers, including lung, bladder and head and neck cancers.
Rong Tang, Xiaomeng Liu, Wei Wang, Jie Hua, Jin Xu, Chen Liang, Qingcai Meng, Jiang Liu, Bo Zhang, Xianjun Yu, Si Shi   +10 more
doaj   +1 more source

Pancreatic Cancer [PDF]

Annual Review of Pathology: Mechanisms of Disease, 2007
The past two decades have witnessed an explosion in our understanding of pancreatic cancer, and it is now clear that pancreatic cancer is a disease of inherited (germ-line) and somatic gene mutations. The genes mutated in pancreatic cancer include KRAS2, p16/CDKN2A, TP53, and SMAD4/DPC4, and these are accompanied by a substantial compendium of genomic ...
Anirban, Maitra, Ralph H, Hruban
openaire   +2 more sources

Gemcitabine: Progress in the treatment of pancreatic cancer [PDF]

, 2001
Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3-5 months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may no longer be regarded a chemotherapy-resistant tumor.
Heinemann, Volker
core   +1 more source

Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. [PDF]

, 2013
Copyright: 2013 Hermann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source ...
Tunici, P, Stephan A. Hahn (423002), Hidalgo Manuel, Annette Bakker (109705), Trabulo Sara M., Hermann, PC, Hahn, SA, Patrizia Tunici (109691), Patrick C. Hermann, Hahn Stephan A., Vandana, M, Sanjeeb K. Sahoo (176483), Sahoo Sanjeeb K., Sainz, B, Sainz Bruno, Anamaria Balic (423000), Garcia Elena, Tunici Patrizia, Manuel Hidalgo, Balic, A, Balic Anamaria, Stephan A. Hahn, Vandana Mallaredy, Elena Garcia (423001), Stephan A Hahn, Christopher Heeschen (373899), Sahoo, SK, Patrizia Tunici, Bakker Annette, Mallaredy Vandana, Heeschen Christopher, Patrick C Hermann, Bruno Sainz, Sara M Trabulo, Sara M. Trabulo, Christopher Heeschen, Patrick C. Hermann (422997), Garcia, E, Mallaredy Vandana (423003), Elena Garcia, Sanjeeb K Sahoo, Heeschen, C, Manuel Hidalgo (7235), Bakker, A, Bruno Sainz Jr (422999), Sanjeeb K. Sahoo, Hermann Patrick C., Sara M. Trabulo (422998), Trabulo, SM, Anamaria Balic, Hidalgo, M, Annette Bakker   +51 more
core   +1 more source

Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis

Molecular Cancer, 2021
Background Extensive studies have demonstrated the pivotal roles of circular RNAs (circRNAs) in the occurrence and development of different human cancers. However, the expression and regulatory roles of circRNAs in pancreatic ductal adenocarcinoma (PDAC)
Zeyin Rong, Si Shi, Zhen Tan, Jin Xu, Qingcai Meng, Jie Hua, Jiang Liu, Bo Zhang, Wei Wang, Xianjun Yu, Chen Liang   +10 more
doaj   +1 more source

Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions

Journal of Hematology & Oncology, 2018
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation)therapy is the main treatment approach. However,
Yiyin Zhang, Chao Yang, He Cheng, Zhiyao Fan, Qiuyi Huang, Yu Lu, Kun Fan, Guopei Luo, Kaizhou Jin, Zhengshi Wang, Chen Liu, Xianjun Yu   +11 more
doaj   +1 more source

The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer: a propensity score matched analysis [PDF]

, 2022
Background: The impact of pancreatic and periampullary cancer treatment on health-related quality of life (HRQoL) is unclear. Methods: This study merged data from the Netherlands Cancer Registry with EORTC QLQ-C30 and -PAN26 questionnaires at baseline ...
Dutch Pancreatic Cancer Group
core